METASTATIC PROSTATE ADENOCARCINOMA
Clinical trials for METASTATIC PROSTATE ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests whether a new cell therapy called STEAP1 CAR T, given together with the hormone drug enzalutamide, is safe and effective for men with metastatic castration-resistant prostate cancer (mCRPC). The therapy uses a patient's own immune cells, modified in the lab to be…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a longer break between prostate cancer treatments boost quality of life?
Disease control Recruiting nowThis phase 3 trial for men with advanced, hormone-resistant prostate cancer tests whether giving the drug lutetium-177 PSMA less often (only when the disease shows signs of activity) can improve quality of life without shortening survival. About 1,500 participants will be randoml…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to halt tough prostate cancer
Disease control Recruiting nowThis study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if the combination can stop or shrink tumors. Participants must have non-measurable disease o…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Triple therapy may extend lives in advanced prostate cancer
Disease control Recruiting nowThis study tests whether adding the chemotherapy drug docetaxel to the usual hormone therapy and apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 men will be randomly assigned to receive either the three-drug combinati…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for tough prostate cancer? drug combo enters early trial
Disease control Recruiting nowThis early-phase trial is testing whether adding ruxolitinib to the standard drug enzalutamide can help men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The study will enroll 20 participants to find the safest dose and check for early s…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo aims to supercharge prostate cancer radiation
Disease control Recruiting nowThis study tests whether giving abemaciclib before a radioactive drug (177Lu-PSMA-617) can make prostate cancer cells more sensitive to radiation. About 30 men with advanced, treatment-resistant prostate cancer will receive abemaciclib pills for two weeks, then the radioactive th…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo therapy aims to slow advanced prostate cancer
Disease control Recruiting nowThis study tests whether adding a special hormone therapy (bipolar androgen therapy) to a targeted radiation drug (radium-223) can slow the growth of prostate cancer that has spread to bones and stopped responding to standard hormone treatments. About 47 men with this advanced ca…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New combo aims to make resistant prostate cancer vulnerable to radiation
Disease control Recruiting nowThis phase 2 trial tests whether adding vorinostat to the radioactive drug 177Lu-PSMA-617 can help men with PSMA-low metastatic castration-resistant prostate cancer. The goal is to increase PSMA levels on cancer cells so the radiation therapy works better. About 15 participants w…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo targets advanced prostate cancer in phase 2 trial
Disease control Recruiting nowThis study tests whether adding the drug talazoparib to standard hormone therapy can better control advanced prostate cancer that still responds to hormone treatment. About 70 men with cancer that has spread will receive the combination. The goal is to see if this approach lowers…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could High-Dose testosterone boost chemo against Hard-to-Treat prostate cancer?
Disease control Recruiting nowThis phase 2 trial tests whether giving high levels of testosterone alongside chemotherapy (carboplatin or etoposide) or a targeted radioactive drug (LuPSMA) can shrink tumors in men with advanced prostate cancer that has stopped responding to hormone therapy. The study will enro…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New smart drug targets cancer cells while sparing healthy ones
Disease control Recruiting nowThis study tests a new medicine, GSK5764227, that delivers a toxin directly to cancer cells to destroy them while leaving healthy cells alone. It is given together with standard treatments to people with advanced solid tumors like colorectal or prostate cancer. The main goals are…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Blood test aims to spot hidden cancer cells in 9 tumor types
Knowledge-focused Recruiting nowThis study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC